1Miao-Wang Hao Li Liu,Department of Internal Medicine,Tangdu Hospital,Xi’an 710038,Shaanxi Province,China Ying-Rui Liang Ming-Yao Wu Huan-Xing Yang,Department of Pathology,Medical College of Shantou University,Shantou 515031,Guangdong Province,China Yan-Fang Liu,Department of Pathology,Fourth Military Medical University,Xi’an 710032,Shaanxi Province,China.Transcription factor EGR-1 inhibits growth of hepatocellular carcinoma and esophageal carcinoma cell lines[J].World Journal of Gastroenterology,2002,8(2):203-207. 被引量：24
2Gang Zhang,Department of Pathophysiology,The Third Military Medical University,Chongqing 400038,China Mian Long Zhe-Zhi Wu Wei-Qun Yu,College of Bioengineer,Chongqing university,Chongqing 400044,China.Mechanical properties of hepatocellular carcinoma cells[J].World Journal of Gastroenterology,2002,8(2):243-246. 被引量：19
4Su CQ, Sham J, Xue HB, et al. Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting telomerase-positive cancer cells. J Cancer Res Clin Oncol,2004 ,130 :591-603.
5LIU T C, GALANIS E, KIRN D. Clinical trial results with oneolytie virotherapy: a century of promise, a deeade of progress[ J]. Nat Clin Pract Oncol, 2007, 4(2) : 101 -117.
6QIAN Q, SHAM J, CHE X, et al. C, enevial vectors : a promising way to target tumor cells and express antieancer genes simuhaneously[J]. ChinMedJ(Engl),2002, 115(8): 1213 -1217.
7SU C Q, SHAM J, XUE I-I B, et al. Potent antitumoral efficacy of a novel replicative adenovirus CNHK300 targeting telomerase -positive cancer cells[J]. J Cancer Res Clin Oncol, 2004, 130 (10) : 591 -603.
8WIRTH T, ZENDER L, SCHULTE B, et al. A telomerase -dependent conditionally replicating adenovirus for selective treatment of cancer[J]. Cancer Res, 2003, 63( 12): 3181 -3188.
9ZHANG Q, NIE M, SHAM J, et al. Effective gene-viral therapy for telomerase-positive cancers by selective replicative-competent adenovirus combining with endostatin gene [ J ]. Cancer Res, 2004, 64(15), 5390-5397.
10SCHMIDINGER M, STEGER G G, WENZEL C, et al. Sequential administration of interferon gamma and interlcukin-2 in metastatic renal cell carcinoma: results of a phase Ⅱ trial. Austrian Renal Cell Carcinoma Study Group[J]. Cancer Immunol Immunother, 2000, 49 (7) : 395-400.
